FINWIRES · TerminalLIVE
FINWIRES

Delta-Fly Pharma Completes Patient Enrolment in Phase 2 Portion of Pancreatic Cancer Study

By

Biotech firm Delta-Fly Pharma (TYO:4598) has completed patient enrolment for the phase 2 portion of its clinical trial testing an experimental drug for pancreatic cancer, according to a Tokyo bourse filing on Thursday.

The study, known as DFP-17729, is a double-blind, randomised, placebo-controlled trial that combines the company's drug with TS-1, an existing oral chemotherapy, in patients with advanced or recurrent pancreatic cancer that cannot be surgically removed.

The trial uses an adaptive design, meaning the results from the phase 2 portion will determine how many patients are needed for the phase 3 portion. If the drug shows a clear benefit in overall survival, the study can move quickly into the next phase.

If successful, DFP-17729 could offer patients a new treatment option that is taken orally, has a strong safety profile, and is cost-effective. The drug works by neutralising the acidic environment around tumours, which helps slow cancer growth without the serious side effects often seen with other treatments.

Related Articles

Asia

YNBY International Launches Share Buyback Program

YNBY International (HKG:0030) launched a share buyback program to repurchase up to 953.8 million ordinary shares, according to a Thursday Hong Kong bourse filing.The shares will be bought back from the market from time to time for a maximum total amount of HK$39 million.

$HKG:0030
Asia

NSK Keeps Final Dividend Steady for Fiscal Year 2025

NSK (TYO:6471) declared a year-end dividend of 17 yen per share for the fiscal year 2025, matching earlier forecasts and also unchanged from the amount paid a year ago.The total dividend payment amounts to 8.48 billion yen, payable from retained earnings on June 8, according to a Tokyo bourse filing on Thursday.The company's policy places great importance on providing stable shareholder returns as part of its mid-term management plan, targeting a dividend payout ratio ranging from 30% to 50% while maintaining a dividend on equity ratio of approximately 2.5% as a lower limit.For the fiscal year 2026, NSK forecasts full-year dividends of 34 yen per share, consisting of an interim dividend of 17 yen and a year-end dividend of 17 yen.

$TYO:6471
Asia

Fujitsu Declares Higher Final Dividend in Fiscal Year 2025

Fujitsu (TYO:6702) declared a year-end dividend of 35 yen per share for the fiscal year 2025, matching earlier forecasts and also higher than the 14 yen per share paid a year ago.The total dividend payment amounts to 60.7 billion yen, payable from retained earnings on June 8, according to a Tokyo bourse filing on Thursday.The company's basic policy targets a consolidated dividend payout ratio that supports sustainable growth and shareholder returns.For the fiscal year 2026, Fujitsu forecasts full-year dividends of 55 yen per share, consisting of an interim dividend of 25 yen and a year-end dividend of 30 yen.

$TYO:6702